April 22, 2012

A lot has happened across GlaxoSmithKline’s consumer division in the past year. Drug Store News spoke with GSK Consumer chief marketing officer John Graham and chief customer officer Keith Loranger about the next move to be made out of the consumer division’s new playbook.

April 21, 2012

It was about a year ago that GlaxoSmithKline organized a dedicated sales team in support of community pharmacy. Drug Store News met with Jack Bailey, GSK SVP policy payers and vaccines, to discuss the progress of that team and the focus being discussed here at NACDS Annual.

September 5, 2014

Mylan on Friday announced that it has launched a generic version of Hoffmann-La Roche's Boniva injection.

August 21, 2014

GlaxoSmithKline announced FDA approval for Arnuity Ellipta (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid medicine for the treatment of asthma in patients 12 years of age and older.

August 19, 2014

"The consumer healthcare market has experienced a steady stream of mergers and acquisitions in recent years. Some of this has created small ripples — like pebbles being gently tossed into still waters. Then there are the mega-mergers that have had a tsunami-like effect," writes Dave Wendland, Hamacher Resource Group VP, in his latest blog entry.

August 14, 2014

Amneal Pharmaceuticals announced four new additions to its portfolio of generic drugs, which represent multiple therapeutic categories and account for $900 million annually in U.S. sales, the company said, citing data from IMS Health.

July 24, 2014

GlaxoSmithKline announced that the Food and Drug Administration has approved Flonase Allergy Relief as an over-the-counter treatment.

July 23, 2014

Mylan on Wednesday announced that U.S. District Court for the district of New Jersey granted a temporary restraining order against Apotex Inc. and Apotex Corp. relating to Paroxetine CR.

July 22, 2014

Lupin, along with certain U.S. drugmakers and private equity funds, mght be making plans to bid for a selection of older drugs from GlaxoSmithKline, according to Reuters, which cited sources familiar with the dealings.

July 21, 2014

Teva Pharmaceutical Industries on Monday announced that its acquistion of Labrys has been completed. The acquisition brings to Teva LBR-101, which is currently in phase-2b clinical trials for prevention of chronic and episodic migraines.

July 17, 2014

Mylan on Thursday announced that the U.S. District Court for the district of New Jersey granted its motion for a permanent injunction against GlaxoSmithKline in relation to paroxetine CR, the generic version of GSK's Paxil CR.

May 29, 2014

Mylan on Thursday announced that it has launched atovaquone and proguanil hydrochloride tablets, 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline's Malarone tablets.

May 16, 2014

These are interesting times to be in the OTC business, Matt Mannelly, Prestige Brands president and CEO, told analysts Thursday.

May 6, 2014

Axium Healthcare Pharmacy on Tuesday announced that it has been accepted into the GlaxoSmithKline Oncology network.

May 1, 2014

GlaxoSmithKline on Wednesday announced that the Food and Drug Administration approved Incruse Ellipta (umeclidinium), which is used for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, or COPD, including chronic bronchitis and/or emphysema.

April 28, 2014

GlaxoSmithKline and Theravance on Monday announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder), a once-daily that combines two long-acting bronchodilators in a single inhaler, is now available in retail pharmacies in the United States.

April 25, 2014

This year the 18th Annual Webby Awards, an international award honoring excellence on the Internet, featured applications for health and wellness mobile health apps, including CVS/pharmacy, Walgreens and GlaxoSmithKline.

April 24, 2014

Endo International announced that its affiliates have acquired rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use from Zogenix.

April 22, 2014

Following a multifaceted deal with Novartis on Tuesday, GlaxoSmithKline and Novartis have created a consumer healthcare giant with annual worldwide revenues of $11 billion on a 2013 pro forma basis.

April 22, 2014

Novartis on Tuesday made a number of moves that have fundamentally reshaped its business, according to published reports.

April 21, 2014

GlaxoSmithKline and Genmab A/S announced last week that the Food and Drug Administration has approved a supplemental biologic license application for the use of Arzerra (ofatumumab) in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia for whom fludarabine-based therapy is considered inappropriate.

April 15, 2014

Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by Design, on Tuesday announced that it has entered into a global licensing agreement with Mylan for its leading inhaled respiratory products, PSX1001 and PSX1050.

March 26, 2014

GlaxoSmithKline began alerting consumers that some bottles of its Alli over-the-counter weight-loss medication have been tampered with.

March 25, 2014

The Food and Drug Administration last week approved Amneal Pharmaceuticals' abbreviated new drug application for atovaquone oral suspension USP, 750-mg/5-mL.